

**Carlo Selmi, MD PhD**  
*Curriculum vitae et studiorum*

**Date and place of birth**      October 6<sup>th</sup>, 1973 – Legnano (Milan, Italy)

**e-mail:**                              carlo.selmi@unimi.it

## Education and Licenses.

July 1998	M.D., University of Milan, Italy ( <i>summa cum laude</i> )
June 1999	Licensed for unrestricted practice of general medicine in Italy
December 2002	Ph.D. in Internal Medicine, University of Milan, Italy ( <i>summa cum laude</i> )
October 2006	Italian Board certified for specialist practice in liver and metabolic diseases

## Clinical and Research Experience.

March-June 1996	Student fellow with a <b>Travel Bursary</b> at the Division of Gastroenterology and Nephrology, University of Lerida, Spain (Bursary program coordinator: Prof. Bruno Andreoni, European Institute of Oncology, Milan)
1998-2002	<b>Ph. D. fellowship</b> in Internal Medicine at the Liver Unit of the Division of Internal Medicine, Institute of Biomedical Science San Paolo Hospital, University of Milan (Director: Prof. Mauro Podda)
June 1999 - August 2001	<b>Research and clinical duties</b> at the Division of Internal Medicine, San Paolo School of Medicine (Director: Prof. Mauro Podda)
2001-2004	<b>Post-doctoral researcher</b> at the Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California, Davis (Director: Dr. M. Eric Gershwin)
July 2005 -	<b>Assistant Adjunct Professor</b> of Medicine at the Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California, Davis (Director: Dr. M. Eric Gershwin)
April 2006 -	<b>Assistant Professor</b> of Internal Medicine and, since 2011, Rheumatology, University of Milan, Italy
September 2008 -	<b>Physician scientist and laboratory head</b> at Humanitas Clinical and Research Center, Rozzano, Milan, Italy
November 2012 -	<b>Head</b> , Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

**Current research interests.**

1. Epigenetics of autoimmune and chronic inflammatory diseases, particularly systemic sclerosis, inflammatory bowel diseases, and autoimmune liver disease. This interest is mirrored by the collection over the past years of unique series of monozygotic twins both discordant and concordant for these conditions. We are currently searching for twins discordant and concordant for psoriatic disease.
2. Clinical epidemiology of autoimmunity and chronic inflammatory disease. This interest is represented by unique population-based case-finding studies to unravel the prevalence of serum autoantibodies. Ongoing studies include longitudinal population-based studies and the determination of the disease natural history based on the large Milan cohort of patients with over 400 cases followed for a median duration of 20 years.
3. Twin studies in chronic inflammatory diseases, particularly psoriasis and psoriatic arthritis
4. Identification of new serum autoantibodies in seronegative autoimmune and chronic inflammatory disease
5. Socioeconomic factors of autoimmune diseases. The study is based on public databases with data mining approaches.

### **Funding history.**

- 2014 Principal Investigator in the Young Investigator Grant from the Italian Ministry of University and Research (MIUR) for the project '*Do autoantibodies predict autoimmune diseases? A population-based study with a follow-up if 13 years*', duration 2014/2017, total direct costs euro 840,000.
- 2010 Principal Investigator in the PSC Partners Seeking a Cure seed grant for the project '*Epigenetics of primary sclerosing cholangitis in monozygotic twins discordant for the disease*', duration 11-01-2010/10-31-2012, total direct costs \$40,000.
- 2010 Principal Investigator in the AARDA grant for the project '*Epigenetics of primary biliary cirrhosis in monozygotic twins*', duration 11-01-2010/10-31-2012, total direct costs \$18,000.
- 2006 Co-investigator in the National Institute of Health R01 grant proposal '*Epidemiology of PBC: a genome-wide association study*' (P.I. M. Eric Gershwin, Michael F. Seldin), duration 10-01-2006/19-30-2011, total direct costs \$2,637,405,000.
- 2006 Principal investigator in the American Liver Foundation (ALF) PBC Research Award for the project '*Epigenetics of the X linked genes in PBC: Does X mark the spot?*', duration 07-01-2006/06-30-2008, amount \$200,000
- 2007 Principal investigator in the National Institute of Health R21 grant proposal '*Epigenetics in primary biliary cirrhosis*', duration 07-01-2006/06-30-2008, total direct costs \$250,000.
- 2008 Principal investigator in the Scleroderma Foundation grant proposal '*Epigenetics in scleroderma*', duration 07-01-2007/06-30-2009, total direct costs \$200,000.

### **Active Memberships to Scientific Societies.**

- ACR (American College of Rheumatology)
- AAI (American Association of Immunologists)

### **Active Participation to International Study Groups.**

- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, GRAPPA (chair: Henning Boehncke)
- National Institute of Environmental Health Sciences (NIEHS) Expert Panel for Environmental Factors in Autoimmunity (chair: Michael C. Humble, Research Triangle Park, NC)
- International Autoimmune Hepatitis Group (IAIHG, chair: Diego Vergani, London, UK)
- International Primary Sclerosing Cholangitis Group (IPSCG, chair: Erik Schrupf, Oslo, Norway).

### **Editorial board memberships.**

- *Clinical Reviews Allergy and Immunology* (Associate Editor)
- *Journal of Autoimmunity*
- *Seminars in Immunopathology*
- *Autoimmunity Highlights*

### **Referee activity for scientific journals.**

*Arthritis and Rheumatism, Clinical and Experimental Medicine (Maywood), Clinical Gastroenterology and Hepatology, Digestive and Liver Diseases, European Journal of Cancer, Gastroenterology, Gut, Hepatology, Journal of Autoimmunity, Journal of Experimental Medicine, Journal of Gastroenterology and Hepatology, Journal of Hepatology, Journal of Immunology, Journal of Medicinal Foods, Lancet, Pediatrics, PLOS Medicine, PLOS ONE*

## BIBLIOMETRICS AND LIST OF PUBLICATIONS

**\*\* Total impact factor** (*Journal Citation Report, 2012 Edition*): **1132**

**\*\* Google Scholar ® H index**: **43**

---

### A. FULL PAPERS (*CURRENT CONTENTS – LIFE SCIENCES*)

#### 2001

---

1. Battezzati P.M., Zuin M., Crosignani A., Allocca M., Invernizzi P., **Selmi C.**, Villa E., Podda M. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. *Aliment Pharmacol Ther* 2001;15:1427-34

#### 2002

---

2. Invernizzi P., Biondi M.L., Battezzati P.M., Perego F., **Selmi C.**, Cecchini F., Podda M., Simoni G. Presence of fetal DNA in maternal plasma decades after pregnancy. *Hum Genet* 2002;110:587-91

#### 2003

---

3. **Selmi C.**, Zuin M., Biondi M.L., Invernizzi P., Battezzati P.M., Bernini M., Meda F., Gershwin M.E., Podda M. Genetic variants of the endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. *J Gastroenterol Hepatol* 2003;18:1150-5

4. **Selmi C.**, Invernizzi P., Tripputi P., Battezzati P.M., Bignotto M., Zuin M., Crosignani A., Podda M. T-cell receptor polymorphism in primary biliary cirrhosis: a case control study. *Ann Ital Med Int* 2003;18:149-53

5. **Selmi C.**, Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., Leung P., Kenny T.P., Van de Water J., Kurth M.J., Nantz M.H., Gershwin M.E. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic metabolizing bacterium. *Hepatology* 2003;38:1250-7

#### 2004

---

6. Invernizzi P., Miozzo M., Battezzati P.M., Bianchi I., Grati F.R., Simoni G., **Selmi C.**, Watnik M., Gershwin M.E., Podda M. The frequency of monosomy X in women with primary biliary cirrhosis. *Lancet* 2004;363:533-5

7. **Selmi C.**, Invernizzi P., Keefe E.B., Coppel R.L., Podda M., Rossaro L., Ansari A.A., Gershwin M.E. Epidemiology and pathogenesis of primary biliary cirrhosis. *J Clin Gastroenterol* 2004;38:264-71

8. **Selmi C.**, Mayo M.J., Bach N., Ishibashi H., Invernizzi P., Gish R.G., Gordon S.T., Wright H.I., Zweiban B., Podda M., Gershwin M.E. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. *Gastroenterology* 2004;127:485-92

9. **Selmi C.**, Ross S., Ansari A.A., Invernizzi P., Podda M., Coppel R.L., Gershwin M.E. Lack of serological, histochemical, or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. *Gastroenterology* 2004;127:493-501

10. **Selmi C.**, Olafsson S., Gudjonsson H., Amano K., Invernizzi P., Podda M., Gershwin M.E. Anti-mitochondrial antibodies and reactivity to *N. aromaticivorans* proteins in Icelandic patients with primary biliary cirrhosis and relatives. *Am J Gastroenterol* 2004;99:2143-6

11. **Selmi C.**, Gershwin M.E. Bacteria and human autoimmunity: the case of primary biliary cirrhosis. *Curr Opin Rheumatol* 2004;16:406-10

---

12. Gershwin M.E., **Selmi C.** Apocalypsal versus apocryphal: the role of retroviruses in primary biliary cirrhosis. *Am J Gastroenterol* 2004;99:2356-8
13. **Selmi C.**, Invernizzi P., Miozzo M., Podda M., Gershwin M.E. Primary biliary cirrhosis: does X mark the spot? *Autoimmun Rev* 2004; 3:493-9

## 2005

---

14. **Selmi C.**, Ichiki Y., Invernizzi P., Podda M., Gershwin M.E. The enigma of primary biliary cirrhosis. *Clin Rev Allergy Immunol* 2005;28:73-81
15. Ichiki Y., **Selmi C.**, Shimoda S., Ishibashi H., Gordon S.C., Gershwin M.E. Mitochondrial antigens as targets of cellular and humoral autoimmunity in primary biliary cirrhosis. *Clin Rev Allergy Immunol* 2005;28:83-91
16. **Selmi C.**, Kimura Y., Leung P.S.C., Mao T.K., Schauer J., Watnik M., Kuriyama S., Nishioka M., Ansari A.A., Coppel R.L., Invernizzi P., Podda M., Gershwin M.E. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. *Hepatology* 2005;41:55-63
17. **Selmi C.**, Battezzati P.M., Shoenfeld, Y., Gershwin M.E. Vaccines in the 21st Century: the genetic response and the innocent bystander. *Autoimmun Rev* 2005;4:79-81
18. Janka C., **Selmi C.**, Gershwin M.E., Will H., Sternsdorf T. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. *Hepatology* 2005;41:609-16
19. Padgett K.A., **Selmi C.**, Kenny T.P., Leung P.S.C., Balkwill D.L., Ansari A.A., Coppel R.L., Gershwin M.E. Phylogenetic and immunological definition of four lipoylated proteins from *Novosphingobium aromaticivorans*, implications for primary biliary cirrhosis. *J Autoimmun* 2005; 24: 209-19
20. Oertelt S., **Selmi C.**, Invernizzi P., Podda M., Gershwin M.E. Genes and goals: an approach to microarray analysis in autoimmunity. *Autoimmun Rev* 2005;4:414-22
21. Kikuchi K., Lian Z.X., Kimura Y., **Selmi C.**, Yang G.X., Gordon S.C., Invernizzi P., Podda M., Coppel R.L., Ansari A.A., Ikehara S., Miyakawa H., Gershwin M.E. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. *J Autoimmun* 2005;25:347-52
22. Giorgini A., **Selmi C.**, Invernizzi P., Podda M., Zuin M., Gershwin M.E. Primary biliary cirrhosis: an overview. *Ann NY Acad Sci* 2005;1051:185-93
23. **Selmi C.**, Zuin M., Gershwin M.E. The bile duct cell: a bully or a victim? *Liver Transpl* 2005;11:878-80
24. Oertelt S., Invernizzi P., **Selmi C.**, Podda M., Gershwin M.E. Soluble CD40L in plasma of patients with primary biliary cirrhosis. *Ann NY Acad Sci* 2005;1051:205-10
25. Invernizzi P., Miozzo M., **Selmi C.**, Persani L., Battezzati P.M., Zuin M., Lucchi S., Meroni P.L., Marasini B., Zeni S., Watnik M., Grati F., Simoni G., Gershwin M.E., Podda M. X chromosome monosomy: a common mechanism for autoimmune diseases. *J Immunol* 2005;175:575-8
26. Rieger R., Oertelt S., **Selmi C.**, Invernizzi P., Podda M., Gershwin M.E. Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity? *Ann NY Acad Sci* 2005;1051:211-7
27. **Selmi C.**, Invernizzi P., Zuin M., Podda M., Gershwin M.E. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. *Semin Liver Dis* 2005;25:265-80
28. Invernizzi P., **Selmi C.**, Ranftler C., Podda M., Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. *Semin Liver Dis* 2005;25:298-310
29. **Selmi C.**, Invernizzi P., Zuin M., Podda M., Seldin M.F., Gershwin M.E. Genes and (auto)immunity in primary biliary cirrhosis. *Genes Immun* 2005;6:543-56
30. **Selmi C.**, Mao T.K., Lian Z.X., Ichiki Y., Ashwood P., Ansari A.A., Coppel R.L., Shimoda S., Ishibashi H., Gershwin M.E. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. *Hepatology* 2005;42:802-8
31. Gershwin M.E., **Selmi C.**, Worman H.J., Gold E.B., Watnik M., Utts J., Lindor K.D., Kaplan M.M., Vierling J.M. and the USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. *Hepatology* 2005;42:1194-202
32. Invernizzi P., Selmi C, Mackay IR, Podda M, Gershwin ME. From bases to basis: linking genetics to causation in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 2005;3:401-10.

## 2006

---

33. Borchers A.T., **Selmi C.**, Cheema G., Keen C.L., Shoenfeld Y., Gershwin M.E. Juvenile idiopathic arthritis.

Autoimmun Rev 2006;5:279-98

34. **Selmi C.**, Mao T.K., Keen C.L., Schmitz H.H., Gershwin M.E. The anti-inflammatory properties of cocoa flavanols. *J Cardiovasc Pharmacol* 2006;47:S163-71

35. Wesierska-Gadek J., Penner E., Battezzati P.M., **Selmi C.**, Zuin M., Hitchman E., Worman H.J., Gershwin M.E., Podda M., Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. *Hepatology* 2006;43:1135-44

36. Watanabe N., Takashimizu S., Shiraishi K., Kagawa T., Nishizaki Y., Mine T., Akatsuka A., **Selmi C.**, Gershwin M.E. Primary biliary cirrhosis with multinucleated hepatocellular giant cells: implications for pathogenesis of primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 2006;18:1023-1027.

37. Seldin M.F., Shigeta R., Villoslada P., **Selmi C.**, Tuomilehto J., Silva G., Belmont J.W., Klareskog L., Gregerson P.K. Evidence for distinct clustering of northern and southern European population groups. *PLOS Genetics* 2006;2:e143

38. **Selmi C.**, Invernizzi P., Gershwin M.E. The X chromosome and systemic sclerosis. *Curr Opin Rheumatol* 2006;18:601-605

39. Wick G., Andersson L., Hala K., Gershwin M.E., **Selmi C.**, Erf G.F., Lamont S.J., Sgonc R. Avian models with spontaneous autoimmune diseases. *Adv Immunol* 2006;92:71-117

40. **Selmi C.**, Lleo A., Zuin M., Podda M., Rossaro L., Gershwin M.E. Interferon alpha and its contribution to autoimmunity. *Curr Opin Investig Drugs* 2006;7:451-6.

---

## 2007

---

40. Tanaka A., Nezu S., Uegaki S., Mikami M., Okuyama S., Kawamura N., Aiso M., **Selmi C.**, Gershwin M.E., Takahashi S., Takikawa H. The clinical significance of antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. *Ann NY Acad Sci* 2007;1107:259-70

41. **Selmi C.**, Mackay I.R., Gershwin M.E. The lymphoid milieu of the liver. *Semin Liver Dis* 2007;27:129-39

42. Patruno V., Aiolfi S., Costantino G., Murgia R., **Selmi C.**, Malliani A., Montano N. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. *Chest* 2007;131:1393-9

43. Lleo A., Invernizzi P., **Selmi C.**, Coppel R.L., Alpini G., Podda M., Mackay I.R., Gershwin M.E. Autophagy: highlighting a novel player in the autoimmunity scenario. *J Autoimmun* 2007;29:61-8

44. Salunga T.L., Cui Z.G., Shimoda S., Zheng H.C., Nomoto K., Kondo T., Takano Y., **Selmi C.**, Alpini G., Gershwin M.E., Tsuneyama K. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. *J Autoimmun* 2007;29:78-86

45. **Selmi C.**, Miozzo M., Gentilin B., Grati F.R., Sirchia S., Oertelt S., Zuin M., Gershwin M.E., Podda M., Invernizzi P. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. *Hepatology* 2007;46:456-62

46. **Selmi C.**, Gershwin M.E., Lindor K.D., Worman H.J., Gold E.B., Watnjik M., Utts J., Invernizzi P., Kaplan M.M., Vierling J.M., Bowlus C.L., Silveira M.G., Bossi I., USA PBC Epidemiology Group. Quality of life and everyday activities in patients with primary biliary cirrhosis. *Hepatology* 2007;46:1836-43.

47. Abdel-Hady H., Zaki A., Badra G., Lotfy M., **Selmi C.**, Giorgini A., El-Sayed M., Badr R. Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia. *Hepatol Res* 2007;37:1026-33.

48. **Selmi C.** Environmental factors in primary biliary cirrhosis. *Hepatol Res* 2007;37:S370-6.

49. **Selmi C.**, Montano N., Furlan R., Gershwin M.E. Nutrition and inflammation in obstructive sleep apnea syndrome. *Exp Biol Med (Maywood)* 2007;232:1409-13.

50. Marasini B., Ferrari P.A., Solaro N., **Selmi C.** Thyroid dysfunction in women with systemic sclerosis. *Ann NY Acad Sci* 2007;1108:305-11

51. Kikuchi K., Tanaka A., Matsushita M., Kitazawa E., Hosoya N., Kawashima Y., **Selmi C.**, Gershwin M.E., Miyakawa H. Genetic polymorphisms of transforming growth factor beta-1 promoter and primary biliary cirrhosis in Japanese patients. *Ann N Y Acad Sci* 2007;1110:15-22.

52. **Selmi C.**, Bowlus C.L., Keen C.L., Gershwin M.E. Non alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches. *J Med Food* 2007;10:563-5.

53. Invernizzi P., Miozzo M., Oertelt-Prigione S., Meroni P.L., Persani L., **Selmi C.**, Battezzati P.M., Zuin M., Lucchi S., Marasini B., Zeni S., Tabano S., Maitz S., Pasini S., Gershwin M.E., Podda M. X monosomy in female systemic lupus erythematosus. *Ann NY Acad Sci* 2007;1110:84-91.

54. **Selmi C.** One year in autoimmunity. *J Autoimmun* 2007;7:85-93.
55. Oertelt S., Rieger R., **Selmi C.**, Invernizzi P., Ansari A.A., Coppel R.L., Podda M., Leung P.S., Gershwin M.E. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. *Hepatology* 2007;45:659-65.

## 2008

56. Oertelt-Prigione S., Mao T.K., **Selmi C.**, Tsuneyama K., Ansari A.A., Coppel R.L., Invernizzi P., Podda M., Gershwin M.E. Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. *J Autoimmun* 2008;41:92-9
57. Meda F., Zuin M., Invernizzi P., Vergani D., **Selmi C.** Serum autoantibodies: a road map for the clinical hepatologist. *Autoimmunity* 2008;41:27-34.
58. Nakanishi Y., Tsuneyama K., Fujimoto M., Salunga T.L., Nomoto K., An J.L., Takano Y., Iizuka S., Nagata M., Suzuki W., Shimada T., Aburada M., Nakano M., **Selmi C.**, Gershwin M.E. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. *J Autoimmun* 2008;30:42-50.
59. Baio P., Brucato A., Buskila D., Gershwin M.E., Giacomazzi D., Lopez L.R., Luzzati R., Matsuura E., **Selmi C.**, Sarzi-Puttini P., Atzeni F. Autoimmune diseases and infections: controversial issues. *Clin Exp Rheumatol* 2008;26:S74-80.
60. Shimoda S., Harada K., Niuro H., Yoshizumi T., Soejima Y., Taketomi A., Maehara Y., Tsuneyama K., Nakamura M., Komori A., Migita K., Nakanuma Y., Ishibashi H., **Selmi C.**, Gershwin M.E. Biliary epithelial cells and primary biliary cirrhosis: The role of liver-infiltrating mononuclear cells. *Hepatology* 2008;47:958-65.
61. Fujimoto M., Tsuneyama K., Kainuma M., Sekiya N., Goto H., Takano Y., Terasawa K., **Selmi C.**, Gershwin M.E., Shimada Y. Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. *Exp Biol Med (Maywood)* 2008; 233:328-37
62. Siegel S.M., **Selmi C.**, Dottorini L., Antelmi M., Zuin M., Lanfredini M., Gershwin M.E. Late-onset autoimmunity: the paradigm of primary biliary cirrhosis. *Gerontology* 2008;54:193-201
63. Tian C., Plenge R.M., Ransom M., Lee A., Villoslada P., **Selmi C.**, Klareskog L., Pulver A.E., Qi L., Gregersen P.K., Seldin M.F. Analysis and application of European genetic substructure using 300 K SNP information. *PLoS Genet* 2008;4:e4.
64. Zuin M., Giorgini M., **Selmi C.**, Battezzati P.M., Cocchi C.A., Crosignani A., Benetti A., Invernizzi P., Podda M. Acute renal and liver failure during treatment with buprenorphine at therapeutic dose. *Dig Liver Dis* 2008;41:e8-10.
65. Lan R.Y., **Selmi C.**, Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). *J Autoimmun* 2008;31:7-12.
66. **Selmi C.**, Cocchi C.A., Lanfredini M., Keen C.L., Gershwin M.E. Chocolate at heart: the anti-inflammatory impact of cocoa flavanols. *Mol Nutr Food Res* 2008;52:1340-8.
67. Invernizzi P., Pasini S., **Selmi C.**, Miozzo M., Podda M. Skewing of X chromosome inactivation in autoimmunity. *Autoimmunity*. 2008;41:272-7.
68. **Selmi C.**, Zuin M., Gershwin M.E. The unfinished business of primary biliary cirrhosis. *J Hepatol* 2008 49:451-60.
69. Lleo A., Battezzati P.M., **Selmi C.**, Gershwin M.E., Podda M. Is autoimmunity a matter of sex? *Autoimmun Rev* 2008;7:626-30.
70. **Selmi C.** The X in sex: how autoimmune diseases revolve around sex chromosomes. *Best Pract Res Clin Rheumatol* 2008;22:913-22.
71. Invernizzi P., **Selmi C.**, Poli F., Frison S., Floreani A.R., Alvaro D., Almasio P., Rosina F., Marzioni M., Fabris L., Muratori L., Qi L., Seldin M.F., Gershwin M.E., Podda M., Italian PBC Genetic Study Group. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. *Hepatology* 2008 48(6):1906-12.
72. Lleo A., **Selmi C.**, Invernizzi P., Podda M., Coppel R.L., Mackay I.R., Gores G.J., Ansari A.A., Van de Water J.A., Gershwin M.E. The mitochondrial PDC-E2 autoantigen of PBC localizes to apoptotic blebs of human intrahepatic biliary cells. *Hepatology* 2008;49:871-9.
73. Crosignani A., Battezzati P.M., Invernizzi P., **Selmi C.**, Prina E., Podda M. Clinical features and management of primary biliary cirrhosis. *World J Gastroenterol* 2008;14:3313-27
74. **Selmi C.**, Zuin M., Bowlus C.L., Gershwin M.E. AMA-negative primary biliary cirrhosis. *Clin Liver Dis* 2008;12:173-85



---

2009

75. **Selmi C.**, Lleo A., Pasini S., Zuin M., Gershwin M.E. Innate immunity and primary biliary cirrhosis. *Curr Mol Med* 2009;9:45-51.
76. Borchers A.T., **Selmi C.**, Gershwin M.E. Probiotics and immunity. *J Gastroenterol* 2009;44(1):26-46.
77. Shoenfeld Y., **Selmi C.**, Zimlichman E., Gershwin M.E. Geoepidemiology, a new center of gravity, and prime time for autoimmunologists. *J Autoimmun* 2009; 31(4):325-30.
78. Marzioni M., Invernizzi P., Candelaresi C., Maggioni M., Saccomanno S., **Selmi C.**, Rychlicki C., Agostinelli L., Cassani B., Miozzo M., Pasini S., Fava G., Alpini G., Benedetti A. Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. *Dig Liver Dis.* 2009;41:523-33.
79. Kikuchi K., Hsu W., Hosoya N., Moritoki Y., Kajiyama Y., Kawai T., Takai A., Hayami E., **Selmi C.**, Gershwin M.E., Miyakawa H. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. *Hepatology* 2009;39:448-54.
80. Agmon-Levin N., Ram M., Barzilai O., Porat-Katz B.S., Parikman R., **Selmi C.**, Gershwin M.E., Anaya J.M., Youinou P., Bizzaro N., Tincani A., Tzioufas A.G., Cervera R., Stojanovich L., Martin J., Gonzalez-Gay M.A., Valentini G., Blank M., San-Marco M., Rozman B., Bombardieri S., De Vita S., Shoenfeld Y. Prevalence of hepatitis C serum antibody in autoimmune diseases. *J Autoimmun* 2009;32:261-6.
81. Giorgini A., Capsoni F., Podda M., Lleo A., Battezzati P.M., Ongari A.M., **Selmi C.**, Benetti A., Malinverno F., Rossaro L., Gershwin M.E., Zuin M. Treatment with peg-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. *Ann NY Acad Sci* 2009; 1173:847-57.
82. **Selmi C.** A new year in autoimmunity. *Ann NY Acad Sci* 2009; 1173:239-42.
83. Deane S., **Selmi C.**, Naguwa S.M., Teuber S.T., Gershwin M.E. Common variable immunodeficiency: etiological and treatment issues. *Int Arch Allergy Immunol* 2009;150:311-324
84. Kawai T., Hosoya N., Moritoki Y., Kajiyama Y., Watanabe M., Takai A., **Selmi C.**, Gershwin M.E., Miyakawa H., Kikuchi K. Autoantibody IgG subclasses to recombinant antigens and the role of bacterial stimuli in primary biliary cirrhosis. *Hepatology* 2009;39:874-81
85. **Selmi C.**, Gershwin M.E. Environmental factors in primary biliary cirrhosis. *Trends Immunol* 2009; 30:415-20
86. Zhong B., Strnad P., **Selmi C.**, Invernizzi P., Tao G.Z., Caleffi A., Chen M., Bianchi I., Podda M., Pietrangelo A., Gershwin M.E., Omary M.B. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. *Hepatology* 2009; 50:546-54
87. Matthias S., Pfeiffer S., **Selmi C.**, Gershwin M.E. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase neo-epitope. *Clin Rev Allergy Immunol* 2009;38:298-301.
88. **Selmi C.**, Podda M., Gershwin M.E. Old and rising stars in the lymphoid liver. *Semin Immunopathol* 2009; 31:279-82
89. Santambrogio R., Opocher E., Zuin M., **Selmi C.**, Bruno S., Bertolini E., Costa M., Montorsi M. Surgical resection versus laparoscopic ablation in patients with hepatocellular carcinoma and Child A liver cirrhosis. *Ann Surg Oncol* 2009;16:3289-98.
90. Barak V., **Selmi C.**, Schlesinger M., Blank M., Agmon-Levin N., Kalickman I., Gershwin M.E., Shoenfeld Y. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. *J Autoimmun* 2009;33:178-82.
91. Dipaola F., Galli A., **Selmi C.**, Furlan R. Efficacy of medical therapy in a case of idiopathic pulmonary fibrosis due to gastroesophageal reflux disease. *Intern Emerg Med* 2009;4:535-7.
92. **Selmi C.** What is hot in autoimmunity. *Acta Reum Portug* 2009;34:580-8.

---

2010

92. Agmon-Levin N., Shapira Y., **Selmi C.**, Barzilai O., Ram M., Szyper-Kravitz M., Sella S., Katz B.S., Youinou P., Renaudineau Y., Larida B., Invernizzi P., Gershwin M.E., Shoenfeld Y. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. *J Autoimmun* 2010;34:55-8.
93. **Selmi C.**, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. *Autoimmun Rev* 2010;9:A267-70.
94. Pettigrew H.D., **Selmi C.**, Teuber S.S., Gershwin M.E. Mold and human health: separating the wheat from the chaff. *Clin Rev Allergy Immunol* 2010;38:148-55.

95. Bhat A., **Selmi C.**, Naguwa S.M., Cheema G.S., Gershwin M.E. Currents concepts on the immunopathology of amyloidosis. *Clin Rev Allergy Immunol* 2010;38:97-106.
96. Deane S., **Selmi C.**, Teuber S.S., Gershwin M.E. Macrophage activation syndrome in autoimmune diseases. *Int Arch Allergy Immunol* 2010;153:109-20.
97. **Selmi C.**, Gershwin M.E. Autoantibodies in autoimmune liver disease: markers versus epiphenomena. *Gut* 2010;59:712-3.
98. Cerri G., Cocchi C.A., Montagna M., Zuin M., Podda M., Cavallari P., **Selmi C.** Patients with primary biliary cirrhosis do not show post-exercise depression of cortical excitability. *Clin Neurophysiol* 2010;121:1321-8.
99. Fujimoto M., Tsuneyama K., Kinoshita H., Goto H., Takano Y., **Selmi C.**, Keen C.L., Gershwin M.E., Shimada Y. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. *Ann NY Acad Sci* 2010;1190:151-8.
100. Freeman S.L., Fisher L., German J.B., Leung P.S., **Selmi C.**, Gershwin M.E. Dairy proteins and the response to Pneumovax in senior citizens: a randomized, double-blind, placebo-controlled study. *Ann NY Acad Sci* 2010;1190:97-103.
101. **Selmi C.** The worldwide gradient of autoimmune conditions. *Autoimmun Rev* 2010;9:A247-50.
102. Invernizzi P., **Selmi C.**, Gershwin M.E. Update on primary biliary cirrhosis. *Dig Liver Dis* 2010;42:401-8.
103. **Selmi C.**, Gershwin M.E. The etiology mystery in primary biliary cirrhosis. *Dig Dis* 2010;28:105-15.
104. Hov J., Lleo A., **Selmi C.**, Woldseth B., Fabris L., Strazzabosco M., Karlsen T.H., Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. *J Hepatol* 2010;52:712-7.
105. Lu Q., Renaudineau Y., Cha S., Ilei G., Brooks W.H., **Selmi C.**, Tzioufas A., Pers J.O., Bombardieri S., Gershwin M.E., Gay S., Youinou P. Epigenetics in autoimmune disorders: Highlights of the 10th Sjögren's Syndrome Symposium. *Autoimmun Rev* 2010;9:627-30.
106. Liu X., Invernizzi P., Lu Y., Kosoy R., Lu Y., Bianchi I., Podda M., Xu C., Xie G., Macciardi F., **Selmi C.**, Lupuli S., Shigeta R., Ransom M., Lleo A., Lee A.T., Mason A.L., Myers R.P., Peltekian K.M., Ghent C. N., Bernuzzi F., Zuin M., Italian Consortium for Primary Biliary Cirrhosis Genetics ICPBCG, Gregersen P.K., Heathcote E.-J., Hirschfield G.M., Siminovitch K.A., Amos C.I., Gershwin M.E., Seldin M.F. Genome-wide meta-analyses identifies three loci associated with primary biliary cirrhosis. *Nat Genet* 2010;42:658-60.
107. Tsuda M., Torgerson T.R., **Selmi C.**, Gambineri E., Carneiro-Sampaio M., Ciullini Mannurita S., Leung P.S.C., Norman G.L., Gershwin M.E. The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial antibodies. *J Autoimmun* 2010; 35:265-8.
108. **Selmi C.**, Meda F., Kasangian A., Invernizzi P., Tian Z., Lian Z., Podda M., Gershwin M.E. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. *Cell Mol Immunol* 2010; 7:1-10.
109. **Selmi C.** Autoimmunity in 2009. *Autoimmun Rev* 2010; 9:795-800.
110. Bowlus C.L., Li C.S., Karlsen T., Lie B., **Selmi C.** Primary sclerosing cholangitis in African Americans listed for liver transplantation: Unique clinical characteristics and HLA associations. *Liver Transpl* 2010; 16:1324-30.
111. **Selmi C.**, Podda M. Methotrexate for primary biliary cirrhosis: whom is to be trusted? *Dig Dis Sci* 2010;55:3013-5.
112. **Selmi C.**, De Santis M., Cavaciocchi F., Gershwin M.E. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. *Dis Markers* 2010;29:287-99.
113. **Selmi C.**, Vergani D, Mieli-Vergani G. Viruses and autoantibodies in biliary atresia. *Gastroenterology* 2010; 139:1461-4.
114. **Selmi C.**, Torok N.J., Affronti A., Gershwin M.E. Genome variants associated with primary biliary cirrhosis. *Genome Med* 2010;2:5.

---

## 2011

115. **Selmi C.**, Mackay I.R., Gershwin M.E. The autoimmunity of primary biliary cirrhosis and the clonal selection theory. *Immunol Cell Biol* 2011;89:70-80.
116. Mitchell M., Lleo A., Zammataro L., Mayo M.J., Invernizzi P., Bach, N., Gordon S.C., Gershwin M.E., Lasalle J.M., **Selmi C.** Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. *Epigenetics* 2011;6:95-102.
117. **Selmi C.**, De Santis M., Gershwin M.E. Liver involvement in subjects with rheumatic diseases. *Arthr Res Ther* 2011;13:226.

118. **Selmi C.**, Leung P.S., Fisher L., German B., Yang C-Y., Kenny T.P., Cyzewski G.R., Gershwin M.E. The effects of spirulina on anemia and immune function in senior citizens. *Cell Mol Immunol* 2011;8:248-54.
119. Meda F., Folci M., Baccarelli A., **Selmi C.** Epigenetics in autoimmunity. *Cell Mol Immunol* 2011;8:226-36.
120. **Selmi C.**, Papini A.M., Alcaro C., Pugliese P., Gershwin M.E. Environmental pathways to autoimmune diseases: the cases of primary biliary cirrhosis and multiple sclerosis. *Arch Med Sci* 2011; 7:368-80.
121. **Selmi C.** Novel Challenges for the Allergist. *Clin Rev Allergy Immunol* 2011; 41:1-3.
122. Toy E., Balasubramanian S., **Selmi C.**, Li C.S., Bowlus C.L. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. *BMC Gastroenterol* 2011;11:83.
123. **Selmi C.** The evidence does not support a viral etiology for primary biliary cirrhosis. *J Hepatol* 2011;54:1315-6.
124. **Selmi C.** Autoimmunity in 2010. *Autoimmun Rev* 2011;10:725-32.
125. De Santis M., **Selmi C.** The therapeutic potential of epigenetics in autoimmune diseases. *Clin Rev Allergy Immunol* 2011; 42:92-101.
126. **Selmi C.**, Bowlus C.L., Gershwin M.E., Coppel R.L. Primary biliary cirrhosis. *Lancet* 2011;377:1600-9. IF 33.633

## 2012

---

127. Folci M., Meda F., Gershwin M.E., **Selmi C.** Cutting-edge issues in primary biliary cirrhosis. *Clin Rev Allergy Immunol* 2012; 42:342-54.
128. Bizzaro N., Covini G., Rosina F., Muratori P., Tonutti E., Vollalta D., Pesente F., Alessio M.G., Tampoia M., Antico A., Plautzgummer S., Porcelli B., Terzuoli L., Liguori M., Bassetti D., Brusca I., Almasio P.L. Tarantino G., Bonaguri C., Agostinis P., Bredi E., Tozzoli R., Invernizzi P., **Selmi C.** Overcoming a probable diagnosis in antimitochondrial antibody primary biliary cirrhosis: study of 100 sera and review of the literature. *Clin Rev Allergy Immunol* 2012; 42:288-97.
129. **Selmi C.**, Mix E., Zettl U.K. A clear look at the neuroimmunology of multiple sclerosis and beyond. *Autoimmun Rev* 2012; 11:159-62.
130. **Selmi C.**, Meroni P.L., Gershwin M.E. Primary biliary cirrhosis and Sjogren syndrome: autoimmune hepatitis. *J Autoimmun* 2012; 39:34-42.
131. Carp H.J., **Selmi C.**, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. *J Autoimmun* 2012; 38:J266-74.
132. Shapira Y., Agmon-Levin N., **Selmi C.**, Petriková J., Barzilai O., Ram M., Bizzaro N., Valentini G., Matucci-Cerinic M., Anaya J.M., Katz B.S., Shoenfeld Y. Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. *J Autoimmun* 2012; 39:112-6.
133. Graziani G., Cucchiari D., Aroldi A., Angelini C., Gaetani P., **Selmi C.** Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug. *J Neurol Neurosurg Psychiatry* 2012; 83:510-2.
134. Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytilinaiou M.G., Heneghan M.A., **Selmi C.**, Gershwin M.E. Twin studies in autoimmune disease: Genetics, gender and environment. *J Autoimmun* 2012;38:J156-69.
135. **Selmi C.**, Brunetta E., Raimondo M.G., Meroni P.L. The X chromosome and the sex ratio of autoimmunity. *Autoimmun Rev* 2012;11:A531-7
136. Fujimoto M., Tsuneyama K., Fujimoto T., **Selmi C.**, Gershwin M.E., Shimada Y. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. *Dig Liver Dis* 2012;44:767-74.
137. **Selmi C.** Cutting-edge issues in autoimmunity and allergy of the digestive system. *Clin Rev Allergy Immunol* 2012;42:265-8.
138. Insawang T., **Selmi C.**, Cha'on U., Pethlert S., Yongvanit P., Areejitranusorn P., Boonsiri P., Khampitak T., Tangrassameeprasert R., Pinitsoontorn C., Prasongwattana V., Gershwin M.E., Hammock B.D. Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population. *Nutr Metab (Lond)* 2012;9:50.
139. You Z., Wang Q., Bian Z., Liu Y., Han X., Peng Y., Shen L., Chen X., Qiu D., **Selmi C.**, Gershwin M.E., Ma X. The immunopathology of liver granulomas in primary biliary cirrhosis. *J Autoimmun* 2012; 39:216-21.
140. **Selmi C.** Autoimmunity in 2011. *Clin Rev Allergy Immunol* 2012; 43:194-206.
141. Miller F.W., Pollard K.M., Parks C.G., Germolec D.R., Leung P.S., **Selmi C.**, Humble M.C., Rose N.R. Criteria for environmentally associated autoimmune diseases. *J Autoimmun* 2012; 39:253-8.

142. **Selmi C.**, Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., Rose N.R., Gershwin M.E. Mechanisms of environmental influence on human autoimmunity: A national institute of environmental health sciences expert panel workshop. *J Autoimmun* 2012; 39:272-84.
143. **Selmi C.**, Gershwin M.E. The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias. *Clin Rev Allergy Immunol* 2012; 43:207-10.
144. Mangano K., Fagone P., Di Mauro M., Ascione E., Maiello V., Molicic A., Lalic N., Saksida T., Stojanovic I., **Selmi C.**, Farina C., Stosic-Grujicic S., Meroni P.L., Nicoletti F. The immunobiology of apotransferrin in type 1 diabetes. *Clin Exp Immunol* 2012 (*in press*).
145. **Selmi C.**, Feghali-Bostwick C.A., Lleo A., Lombardi S.A., De Santis M., Cavaciocchi F., Zammataro L., Mitchell M.M., LaSalle J.M., Medsger, T. Jr., Gershwin M.E. X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. *Clin Exp Immunol* 2012 (*in press*).
146. Nguyen M.T., Borchers A.T., **Selmi C.**, Naguwa S.M., Cheema G., Gershwin M.E. The SAPHO syndrome. *Semin Arthr Rheum* 2012;42:254-65.
147. **Selmi C.**, Lu Q., Humble M.C.. Heritability versus the role of the environment in autoimmunity. *J Autoimmun.* 2012;39:249-52.
148. Wang Q., **Selmi C.**, Zhou X., Qiu D., Li Z., Miao Q., Chen X., Wang J., Krawitt E.L., Gershwin M.E., Han Y., Ma X. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. *J Autoimmun* 2012 (*in press*)

---

## 2013

---

149. Avrameas S., **Selmi C.** Natural autoantibodies in the physiology and pathophysiology of the immune system. *J Autoimmun.* 2013; 41:46-9.
150. **Selmi C.**, Ceribelli A., Vierling J.M. Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis. *Semin Immunopathol* 2013;35:1-5.
151. Agmon-Levin N., **Selmi C.** The autoimmune side of heart and lung diseases. *Clin Rev Allergy Immunol.* 2013;44:1-5.
152. Achenza M.I.S., **Selmi C.** Autoimmunity and cancer. *Asia Pacif J Cancer prev* 2013 (*in press*)
153. **Selmi C.**, Crotti C., Meroni P.L. Less travelled roads in clinical immunology and allergy: the cases of drug reactions and environmental influence. *Clin Rev Allergy Immunol* 2013; 45:1-5.
154. Sumida K., Shimoda S., Iwasaka S., Hisamoto S., Kawanaka H., Akahoshi T., Ikegami T., Shirabe K., Shimono N., Maehara Y., **Selmi C.**, Gershwin M.E., Akashi K. Spleen CD8<sup>+</sup>T cells exhaustion is enhanced in liver cirrhosis secondary to hepatitis C virus infection. *Clin Exp Immunol* 2013 (*in press*)
155. De Santis M., Crotti C., **Selmi C.** Liver abnormalities in connective tissue disease. *Best Pract Res Clin Gastroenterol* 2013 (*in press*)
156. Tsuneyama K., Baba H., Kikuchi K., Nishida H., Nomoto K., Hayashi S., Miwa S., Nakajima T., Nakanishi Y., Masuda S., Terada M., Imura J., **Selmi C.** Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. *Clin Rev Allergy Immunol* 2013; 45:143-8.
157. Podda M., **Selmi C.**, Lleo A. Moroni L., Invernizzi P. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. *J Autoimmun* 2013 (*in press*)
158. **Selmi C.** Autoimmunity in 2012. *Clin Rev Allergy Immunol* 2013 (*in press*)
159. Sharma A., Prasongwattana V., Cha'on U., **Selmi C.**, Hipkiao W., Boonnate P., Pethlert S., Titipungul T., Intarawichian P., Waraasawapati S., Puapiroj A., Sitprija V., Reungjui S. Monosodium Glutamate (MSG) Consumption Is Associated with Urolithiasis and Urinary Tract Obstruction in Rats. *PLoS One* 2013;8:e75546.
160. Podda M., **Selmi C.**, Lleo A., Moroni L., Invernizzi P. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. *J Autoimmun* 2013;46:81-7.

---

## 2014

---

161. **Selmi C.**, Gershwin M.E. Diagnosis and classification of reactive arthritis. *Autoimmun Rev* 2013 (*in press*)
162. **Selmi C.** Diagnosis and classification of autoimmune uveitis. *Autoimmun Rev* 2013 (*in press*)
163. Fujimoto M., Tsuneyama K., Nakanishi Y., Salunga T.L., Nomoto K., Sasaki Y., Iizuka S., Nagata M., Suzuki W., Shimada T., Aburada M., Shimada Y., Gershwin M.E., **Selmi C.** A dietary restriction influences the progression but not the initiation of MSG-induced non alcoholic steatohepatitis. *J Med Food* 2014 (*in press*)

164. **Selmi C.**, Shoenfeld Y. Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting. *BMC Med* 2014 (in press)
164. **Selmi C.**, Cavaciocchi F., Ileo A., Cheroni C., De Francesco R., Lombardi S.A., De Santis M., Meda F., Raimondo M.G., Crotti C., Folci M., Zammataro L., Mayo M.J., Bach N., Shimoda S., Gordon S.C., Miozzo M., Invernizzi P., Podda M., Martin M.R., Seldin M.F., LaSalle J.M., Gershwin M.E. Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. *Front Immunol* 2014 (in press)

## **B. COLLABORATIVE FULL PAPERS (*CURRENT CONTENTS – LIFE SCIENCES*)**

1. Costantino G, Perego F, Dipaola F, Borella M, Galli A, Cantoni G, Dell'Orto S, Dassi S, Filardo N, Duca PG, Montano N, Furlan R; **STePS Investigators**. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study. *J Am Coll Cardiol* 2008;51:276-83
2. Montali L., Tanaka A., Riva P., Takahashi H., Cocchi C.A., Ueno Y., Miglioretti M., Takikawa H., Vecchio L., Frigerio A., Bianchi I., Jorgensen R., Lindor K.D., Podda M., Invernizzi P., **Italian-Japanese PBC Study Group**. A short version of a HRQoL questionnaire for Italian and Japanese patients with PBC. *Dig Liver Dis* 2010; 42:718-23.
3. Invernizzi P., Ransom M., Raychaudhuri S., Kosoy R., Lleo A., Shigeta R., Franke A., Bossa F., Amos C.I., Gregersen P.K., Siminovitch K.A., Cusi D., de Bakker P.I., Podda M., Gershwin M.E., Seldin M.F., **The Italian PBC Genetics Study Group**. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. *Genes Immun* 2012 (in press)
4. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI; **Italian PBC Genetics Study Group**, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. *Hum Mol Genet.* 2012;21:5209-21.
5. Franchi C, Nobili A, Mari D, Tettamanti M, Djade CD, Pasina L, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM; **REPOSI Investigators**. Risk factors for hospital readmission of elderly patients. *Eur J Intern Med.* 2013 Jan;24(1):45-51.
6. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, Marengoni A, Salerno F, Corrao S, Mannucci PM; **REPOSI (REgistro POLiterapie Società Italiana di Medicina Interna) Investigators**. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med.* 2013 Sep;8(6):509-20.
7. Marengoni A, Nobili A, Piralì C, Tettamanti M, Pasina L, Salerno F, Corrao S, Iorio A, Marcucci M, Franchi C, Mannucci PM; **REPOSI Investigators**. Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. *Gerontology.* 2013;59(4):307-15.

## **C. LETTERS (*CURRENT CONTENTS – LIFE SCIENCES*)**

1. **Selmi C.**, Zuin M., Meda F., Podda M., Biondi M.L., Cecchini F. Common variants of the matrix metalloproteinase-3 (stromelysin) gene promoter in primary biliary cirrhosis. *Gastroenterology* 2002;122: 247-8
2. **Selmi C.**, Ross S.R., Ansari A.A., Invernizzi P., Podda M., Coppel R. L., Gershwin M.E. Reply to Dr. Mason. *Gastroenterology* 2004;127:1864-5
3. **Selmi C.**, Gershwin M.E. Reply to Dr. Freeman. *Gastroenterology* 2004;127:1645
4. Busatto P., Blasi F., Casanova F., **Selmi C.**, Centanni S., Zuin M. Lack of PBC-specific antimitochondrial antibodies in patients with Chlamydia pneumoniae infection. *J Gastroenterol Hepatol* 2005;20:1626-7
5. Invernizzi P, **Selmi C.**, Zuin M., Podda M. Lack of serum antibodies to membrane-bound carbonic anhydrase IV in primary biliary cirrhosis. *Gut* 2005;54:1665
6. **Selmi C.**, Gershwin M.E. The retroviral myth of primary biliary cirrhosis: is this (finally) the end of the

story? J Hepatol 2009; 51:412-3

7. **Selmi C.**, Gershwin M.E. Reply to: Functional autoantibodies in primary biliary cirrhosis. Trends Immunol 2010.

8. Costantino G., Dipaola F., **Selmi C.**, Furlan R. Orthostatic intolerance and coronary reserve: a matter of certain gravity. Emerg Intern Med 2011;6:471-2.

9. Insawang T., **Selmi C.**, Cha On U., Gershwin M.E., Yongvanit P., Prasongwattana V.

Response to Dr. Roger's letter: Further studies are necessary in order to conclude a causal association between the consumption of monosodium L-glutamate (MSG) and the prevalence of metabolic syndrome in the rural Thai population. Nutr Metab (Lond). 2013 Jan 15;10(1):10.

#### **D. FULL ARTICLES IN JOURNALS NOT INCLUDED IN THE *CURRENT CONTENTS – LIFE SCIENCES***

1. Achenza M.I., Meda F., Brunetta E., **Selmi C.** Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol 2012;6:717-29.

2. Marinoni B., Ceribelli A., Massarotti M.S., **Selmi C.** The Th17 axis in psoriatic disease. Autoimmun Highlights 2014 (*in press*)

#### **E. BOOK CHAPTERS**

1. **Selmi C.**, Invernizzi P., Zuin M., Ansari A.A., Gershwin M.E. Evaluation of the immune function in the nutritionally at-risk patient. In: Handbook of Nutrition and Immunity. Gershwin ME, Nestel P, Keen CL, Eds. Humana Press, Totowa, NJ (2004)

2. **Selmi C.**, Oertelt S., Invernizzi P., Podda M., Gershwin M.E. Autoantibody recognition of functional sites. In: M. Pollard Ed. Autoantibodies and autoimmunity: molecular and mechanisms in health and disease. Wiley VCH Verlag GmbH and Co. Weinheim, Germania (2005)

3. **Selmi C.**, Coppel R.L., Gershwin M.E. Primary biliary cirrhosis. In: Autoimmune diseases, 4th Edition. Mackay IR, Rose NR eds. Elsevier Press, London, UK (2006)

4. Oertelt S., **Selmi C.**, Invernizzi P., Podda M., Coppel R.L., Gershwin M.E. Primary biliary cirrhosis and biliary destruction: 2005; a liver odyssey. In: Gut-Liver Interactions: Basic and Clinical Concepts. Blumberg, R.S., M.P. Manns, A. Gangl, H. Tilg and M. Zeitz, eds. Proceedings of the Falk Symposium 146 held in Innsbruck, Austria, March 11-12, 2005, Springer, Olanda (2006)

5. **Selmi C.**, Lleo A., Invernizzi P., Gershwin M.E. Primary biliary cirrhosis and autoimmune cholangitis. In: Liver Immunology: Principles and Practice. Gershwin ME, Vierling JM, Manns MP Eds. Humana Press Publisher (2007)

6. Invernizzi P., Bianchi I., Locati M., Bonecchi R., **Selmi C.** Cytokines in liver health and disease. In: Liver Immunology: Principles and Practice. Gershwin ME, Vierling JM, Manns MP Eds. Humana Press Publisher, (2007)

7. Invernizzi P., **Selmi C.**, Gershwin M.E. Antimitochondrial antibodies. In: Autoantibodies, 2<sup>nd</sup> edition. Shoenfeld, Y., M.E. Gershwin and P.L. Meroni, eds. Elsevier, B.V. Publisher (2007)

8. **Selmi C.**, Muratori P., Podda M., Bianchi F.B. Smooth muscle antibodies. In: Autoantibodies, 2<sup>nd</sup> edition. Shoenfeld, Y., M.E. Gershwin and P.L. Meroni, eds. Elsevier, B.V. Publisher (2007)

9. **Selmi C.**, Invernizzi P., Zuin M., Battezzati P.M., Gershwin M.E. Geoepidemiology of primary biliary cirrhosis. In: Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune. Diehl, A.M., N. Hayashi, M.P. Manns and T. Sauerbruch, eds. Proceedings of the Falk Symposium 157 held in Freiburg, Germany, Springer Publishing, The Netherlands (2006)

10. **Selmi C.**, He X-S., Bowlus C.L., Gershwin M.E. Relationship between primary biliary cirrhosis and lipoic acid. In: Alpha Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects, Patel, M, Packer, L., eds., Taylor and Francis Publishers (2007)

11. Podda M., Invernizzi P., **Selmi C.**, Zuin M. Il fegato in gravidanza. In Zanussi C. Ed, Il Metodo in Medicina Clinica. UTET (2007)

12. Podda M., Invernizzi P., Meda F., **Selmi C.**, Zuin M. Malattie autoimmuni del fegato. In Zanussi C. Ed, Il Metodo in Medicina Clinica. UTET (2007)

13. **Selmi C.**, Manns M.P., Gershwin M.E. Inflammatory hepatobiliary cirrhosis. In: *Clinical Immunology: Principles and Practice*, 3<sup>rd</sup> Edition. Rich, R.R., T.A. Fleisher, W.T. Shearer, H.W. Schroeder, Jr., A.J. Frew and C.M. Weyand, eds., Mosby Elsevier (2008)
14. **Selmi C.**, Gershwin M.E. Cholangitis, autoimmune. In: *Encyclopedia of Molecular Mechanisms of Disease*. Springer Publishing 2009
15. Allocca M., **Selmi C.** Emerging nutritional treatments for non alcoholic fatty liver disease. In Preedy V.R., Lakshman R., Rajaskanthan R.S., Watson R.W., eds. *Nutrition, Diet Therapy and the Liver*, Taylor and Francis, CRC Press, Boca Raton, FL 2009
16. Battezzati P.M., Destrebecq A., Lessio B., Lleo A., Melesi M., **Selmi C.** *Infermieristica clinica in medicina interna*. UTET, Milano 2009
17. **Selmi C.**, Manns M.P., Gershwin M.E. Inflammatory hepatobiliary diseases. In: *Clinical Immunology: Principles and Practice*, 4<sup>th</sup> Edition. Rich, R.R., T.A. Fleisher, W.T. Shearer, H.W. Schroeder, Jr., A.J. Frew and C.M. Weyand, eds., Mosby Elsevier (2011)
18. **Selmi C.** Chighinzola C., Ceribelli A., De Santis M., Meroni P.L., Zhong R. The epidemiology and rheumatology of autoimmune liver disease. In: *Liver Immunology: Principles and Practice*, 2<sup>nd</sup> edition. Gershwin ME, Vierling JM, Manns MP Eds. Humana Press Publisher, (2013)
19. **Selmi C.**, Gershwin M.E. Antimitochondrial antibodies. In: *Autoantibodies*, 3<sup>rd</sup> edition. Shoenfeld, Y., M.E. Gershwin and P.L. Meroni, eds. Elsevier, B.V. Publisher (2013)
20. **Selmi C.**, Ceribelli A. Anti-GAD antibodies. In: *Autoantibodies*, 3<sup>rd</sup> edition. Shoenfeld, Y., M.E. Gershwin and P.L. Meroni, eds. Elsevier, B.V. Publisher (2013)
21. **Selmi C.**, Coppel R.L., Gershwin M.E. Primary biliary cirrhosis. In: *Autoimmune diseases*, 5<sup>th</sup> Edition. Mackay IR, Rose NR eds. Elsevier Press, London, UK (2013)